Cellaria and Biological Industries USA Partner on Stem Cell Media and Research

Co-marketing and sales agreement provides custom stem cell research services

Cambridge, Massachusetts, UNITED STATES

CAMBRIDGE, Mass. and CROMWELL, Conn., May 04, 2017 (GLOBE NEWSWIRE) -- Cellaria, LLC, a scientific innovator that develops revolutionary new patient-specific models for challenging diseases, and Biological Industries USA (BI-USA), a subsidiary of Biological Industries (Israel), today announced a new sales and marketing agreement to promote custom stem cell services. The partnership combines BI-USA’s strength in stem cell culture media and manufacturing with Cellaria’s comprehensive Stem Cell Services program, which includes industry leading RNA reprogramming and custom differentiation services. Together, the companies will offer one of the industry’s most innovative and comprehensive stem cell service offerings available to biotechnology companies and academic institutions.

As part of the agreement, Cellaria will distribute BI-USA’s stem cell media offering, including its NutriStem® hPSC Medium, a cGMP xeno-free media specifically designed for human pluripotent stem cell culture. Cellaria will also incorporate the product into its stem cell services. BI-USA will market Cellaria's customized stem cell services, establishing an integrated, single source solution for iPS cell line derivation, culture maintenance, banking, characterization and differentiation services.

“BI is one of the most respected names in life sciences today,” said David Deems, chief executive officer at Cellaria. “The company’s strong market presence and innovative media products will enhance our stem cell and RNA reprogramming service offerings and significantly increase the availability and appeal of our combined offerings.”

“This is an important partnership for us,” added Tanya Potcova, chief executive officer of BI-USA. “In combination, our teams bring a wealth of stem cell experience but also share a common goal of creating higher quality, more consistent research outcomes for researchers in the life sciences field. We are pleased to be working with the team at Cellaria to put the best possible tools and support in the hands of our present and future customers.”

Please visit Cellaria and BI at the International Society of Stem Cell Research Annual Meeting in Boston, MA June 14-17, 2017 at booth# 407.

About Cellaria
Cellaria creates high quality, next generation in vitro disease models that reflect the unique nature of a patient’s biology. All models begin with tissue from a patient, capturing clinically relevant details that inform model characterization. For cancer, Cellaria’s cell models exhibit molecular and phenotypic characteristics that are highly concordant to the patient. For RNA-mediated iPS cell line derivation and stem cell services, Cellaria’s cell models enable interrogation of patient and disease-specific mechanisms of action. Cellaria’s innovative products and services help lead the research community to more personalized therapeutics, revolutionizing and accelerating the search for a cure. For more information, visit www.cellariabio.com.

About Biological Industries
Biological Industries (BI) is one of the world’s leading and trusted suppliers to the life sciences industry, with over 35 years’ experience in cell culture media development and cGMP manufacturing. BI’s products range from classical cell culture media to supplements and reagents for stem cell research and potential cell therapy applications, to serum-free, xeno-free media. BI is committed to a Culture of Excellence through advanced manufacturing and quality-control systems, regulatory expertise, in-depth market knowledge, and extensive technical customer-support, training, and R&D capabilities.

Biological Industries USA (BI-USA) is the US commercialization arm of BI, with facilities in Cromwell, Connecticut. Members of the BI-USA team share a history and expertise of innovation and success in the development of leading-edge technologies in stem cell research, cellular reprogramming, and regenerative medicine. For more information, visit www.bioind.com or connect on LinkedInTwitter, and Facebook.


Contact Data